Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | AR | P10275 | 7/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624023 | 0.98 | RAB9A (0.58) | RAB9ASMN1; SMN2ARTP53ALOX15 | |
| SCHEMBL30756603 | 0.96 | RAB9A (0.51) | RAB9ASMN1; SMN2ARTP53ALOX15 | |
| SCHEMBL28657476 | 0.84 | AR (0.54) | RAB9ASMN1; SMN2ARTP53ALOX15 | |
| SCHEMBL12288858 | 0.84 | SMN1; SMN2 (0.41) | RAB9ASMN1; SMN2ARTP53ALOX15 | |
| SCHEMBL5416355 | 0.82 | CHRNB2 (0.42) | RAB9ASMN1; SMN2ARHSD17B10NPC1 | |
| SCHEMBL1168974 | 0.82 | ALDH1A1 (0.53) | RAB9ASMN1; SMN2ARNPC1MAPT | |
| SCHEMBL2698786 | 0.82 | NPC1 (0.60) | RAB9ASMN1; SMN2ARNPC1MAPT | |
| SCHEMBL3159092 | 0.82 | CHRNB2 (0.42) | RAB9ASMN1; SMN2ARHSD17B10NPC1 | |
| SCHEMBL2224078 | 0.81 | RAB9A (0.40) | RAB9ASMN1; SMN2ARTP53ALOX15 | |
| SCHEMBL28649670 | 0.80 | RAB9A (0.39) | RAB9ASMN1; SMN2ARTP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054874-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | RAB9A 2748/4885SMN1; SMN2 3748/4885AR 2910/4885 |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | RAB9A 442/4885SMN1; SMN2 1991/4885AR 2627/4885 |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | RAB9A 3925/4885SMN1; SMN2 2370/4885AR 2197/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | RAB9A 463/4885SMN1; SMN2 2007/4885AR 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.